Acarbose: The Diabetes Drug With a Longevity Signal

TL;DR: Acarbose is an old, inexpensive diabetes medicine that blunts the rise in blood sugar after meals by slowing how fast you digest carbohydrates. It drew longevity interest for a striking reason: in a rigorous mouse program it extended lifespan, most in males. In people, the proven human benefit is narrower: it lowers post-meal glucose and reduces the odds that prediabetes turns into type 2 diabetes. It does not, in the best trial, prevent heart attacks. There is no human lifespan data, so its anti-aging promise rests on mice and mechanism rather than proof in people. The main catch is gas and bloating, which limits how many people stick with it.

What is acarbose, and how does it work?

Acarbose is an alpha-glucosidase inhibitor, which is a technical way of saying it slows the enzymes in your gut that break carbohydrates down into sugar. When you eat starch or table sugar, those enzymes normally chop it into glucose quickly, sending a wave of sugar into your blood. Acarbose gets in the way of that step, so the same meal releases its sugar more slowly and the after-meal rise is smaller and gentler.

Almost none of the drug is absorbed; it does its work in the gut and leaves. That local action is why it lowers blood sugar without the whole-body reach of most diabetes drugs, and also why its main side effect is digestive, which we will come to.

Why do longevity researchers care about acarbose?

The interest comes from mice, and from a program built to be hard to fool. The National Institute on Aging runs the Interventions Testing Program, which tests aging compounds in genetically varied mice across three separate labs at once, so a result has to replicate to count. Acarbose passed. In the 2014 report, it extended median lifespan in male mice by about 22%, with a smaller 5% gain in females.¹ A later study confirmed the effect at higher doses and, notably, found that starting acarbose in middle age still lengthened male lifespan, so the benefit did not depend on a lifetime of use.²

Why would a carb-blocker do that? The leading idea is that the daily rise in blood sugar and insulin after meals is one of the pressures that ages us, and softening it, meal after meal, eases that load. It is a plausible bridge from mouse to human, but a bridge is not a destination, and this is where the caution comes in.

What has acarbose been proven to do in people?

In humans, the firm evidence is about blood sugar rather than lifespan. The landmark trial, STOP-NIDDM, gave acarbose to people with prediabetes and found it cut the rate of progression to type 2 diabetes by about 25% over three years.³ That is a meaningful, replicated result: slowing carbohydrate absorption helps keep prediabetes from tipping over into diabetes.

The same trial reported a large drop in cardiovascular events, which generated headlines.⁴ That finding, though, rested on a small number of events, was disputed at the time, and should be read with caution.⁵ The question was settled by a larger, purpose-built trial, which we turn to next.

Does acarbose prevent heart attacks?

No, based on the best evidence. The ACE trial was built to answer this question directly. It gave acarbose to more than 6,000 people in China who had both coronary heart disease and prediabetes, and followed them for about five years. The result on heart attacks, strokes, and cardiovascular death was flat: no benefit over placebo.⁶

But the same trial repeated the one human benefit that does hold up: acarbose reduced the number of people who developed diabetes, by about 18%.⁶ So the summary is narrow and clear. Acarbose is a diabetes-prevention drug with a strong mouse-longevity signal behind it, and it is not a heart-attack-prevention drug.

How is acarbose taken, and what are the downsides?

Acarbose is taken as a tablet with the first bite of each main meal, since it needs to be there when the carbohydrates arrive. The usual approach is to start low, around 25 milligrams three times a day, and increase slowly over weeks toward 50 to 100 milligrams with meals, because a slow ramp is what keeps the side effects manageable.

Those side effects are the main story of acarbose in practice. Because the drug pushes undigested carbohydrate further down the gut, gut bacteria ferment it, and the result is gas, bloating, and loose stools. For many people this is enough to stop the drug, and it is the single biggest reason acarbose is not used more. Eating fewer refined carbohydrates blunts the effect, which is a nudge in a healthy direction anyway.

One safety point matters if you take other diabetes medicines. Acarbose on its own does not cause low blood sugar, but if you also take insulin or a sulfonylurea and your sugar drops too low, you have to treat it with glucose itself, the kind in glucose tablets, rather than with table sugar or juice. Acarbose blocks the breakdown of table sugar, so it will not raise your blood sugar quickly in an emergency. It is a small detail that occasionally matters a great deal.

Guidance from the Clinic

"Acarbose is one of those compounds where I have to separate what excites me from what I can promise. The mouse lifespan data is some of the most reproducible in the field, and the idea of smoothing out the after-meal sugar swings makes sense to me. But when a patient asks whether it will help them live longer, my answer is the plain one: we do not know, because no one has tested that in people, and the one big heart trial came back neutral. Where I do use it is for the person sliding from prediabetes toward diabetes who wants a tool with a long track record, as long as their gut tolerates it. For a healthy person chasing longevity, I would put sleep, muscle, and how they eat far ahead of any pill, acarbose included."

Related at Fishtown Medicine

• Ozempic vs Metformin - other glucose-lowering options compared
• SGLT2 Inhibitors: Heart, Kidney, and Longevity - proven organ protection with a longevity signal
• Rapamycin for Longevity - another drug with animal lifespan data
• Biological Age Testing - measuring how you are aging
• Berberine Clinical Guide - a supplement often compared to metabolic drugs
• Continuous Glucose Monitor in Philadelphia - seeing your after-meal glucose directly

Scientific References

1. Harrison DE, Strong R, Allison DB, et al. "Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males." Aging Cell. 2014;13(2):273-282.
2. Harrison DE, Strong R, Alavez S, et al. "Acarbose improves health and lifespan in aging HET3 mice." Aging Cell. 2019;18(2):e12898.
3. Chiasson JL, Josse RG, Gomis R, et al. "Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial." Lancet. 2002;359(9323):2072-2077.
4. Chiasson JL, Josse RG, Gomis R, et al. "Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial." JAMA. 2003;290(4):486-494.
5. Kaiser T, Sawicki PT. "Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data." Diabetologia. 2004;47(3):575-580.
6. Holman RR, Coleman RL, Chan JCN, et al. "Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial." Lancet Diabetes Endocrinology. 2017;5(11):877-886.